nodes	percent_of_prediction	percent_of_DWPC	metapath
Cinacalcet—CYP3A4—bone cancer	0.757	1	CbGaD
Cinacalcet—CASR—GPCRs, Class C Metabotropic glutamate, pheromone—GRM4—bone cancer	0.0265	0.187	CbGpPWpGaD
Cinacalcet—CASR—GPCRs, Class C Metabotropic glutamate, pheromone—GRM1—bone cancer	0.023	0.163	CbGpPWpGaD
Cinacalcet—CASR—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM4—bone cancer	0.0121	0.0855	CbGpPWpGaD
Cinacalcet—CASR—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM1—bone cancer	0.0105	0.0741	CbGpPWpGaD
Cinacalcet—Metastatic neoplasm—Cisplatin—bone cancer	0.0076	0.0792	CcSEcCtD
Cinacalcet—Renal failure chronic—Cisplatin—bone cancer	0.00541	0.0564	CcSEcCtD
Cinacalcet—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00514	0.0363	CbGpPWpGaD
Cinacalcet—Tetany—Cisplatin—bone cancer	0.00447	0.0466	CcSEcCtD
Cinacalcet—Metastatic neoplasm—Epirubicin—bone cancer	0.0039	0.0407	CcSEcCtD
Cinacalcet—Metastatic neoplasm—Doxorubicin—bone cancer	0.00361	0.0376	CcSEcCtD
Cinacalcet—CASR—E-cadherin signaling in keratinocytes—EGFR—bone cancer	0.00323	0.0228	CbGpPWpGaD
Cinacalcet—CASR—G alpha (q) signalling events—GRM1—bone cancer	0.00306	0.0216	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—RGS1—bone cancer	0.00294	0.0207	CbGpPWpGaD
Cinacalcet—CASR—G alpha (i) signalling events—GRM4—bone cancer	0.00294	0.0207	CbGpPWpGaD
Cinacalcet—Tipranavir—CYP3A4—bone cancer	0.00279	0.511	CrCbGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00273	0.0193	CbGpPWpGaD
Cinacalcet—Multi-organ failure—Epirubicin—bone cancer	0.00229	0.0239	CcSEcCtD
Cinacalcet—Multi-organ failure—Doxorubicin—bone cancer	0.00212	0.0221	CcSEcCtD
Cinacalcet—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.002	0.0141	CbGpPWpGaD
Cinacalcet—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00199	0.0141	CbGpPWpGaD
Cinacalcet—CASR—G alpha (q) signalling events—GNA11—bone cancer	0.00197	0.0139	CbGpPWpGaD
Cinacalcet—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00189	0.0133	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—GRM4—bone cancer	0.00178	0.0126	CbGpPWpGaD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00176	0.0124	CbGpPWpGaD
Cinacalcet—Infection—Carboplatin—bone cancer	0.00176	0.0183	CcSEcCtD
Cinacalcet—Floctafenine—PTGS2—bone cancer	0.00169	0.309	CrCbGaD
Cinacalcet—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00169	0.0119	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—GRM1—bone cancer	0.00154	0.0109	CbGpPWpGaD
Cinacalcet—Body temperature increased—Carboplatin—bone cancer	0.0014	0.0146	CcSEcCtD
Cinacalcet—Multiple fractures—Methotrexate—bone cancer	0.00137	0.0143	CcSEcCtD
Cinacalcet—Fracture—Methotrexate—bone cancer	0.00137	0.0143	CcSEcCtD
Cinacalcet—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0013	0.00921	CbGpPWpGaD
Cinacalcet—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00123	0.00866	CbGpPWpGaD
Cinacalcet—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00115	0.00813	CbGpPWpGaD
Cinacalcet—CASR—GPCR ligand binding—SMO—bone cancer	0.00109	0.00767	CbGpPWpGaD
Cinacalcet—Hypercalcaemia—Epirubicin—bone cancer	0.00108	0.0112	CcSEcCtD
Cinacalcet—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.00106	0.011	CcSEcCtD
Cinacalcet—Thrombosis—Epirubicin—bone cancer	0.00106	0.011	CcSEcCtD
Cinacalcet—Ventricular arrhythmia—Epirubicin—bone cancer	0.00101	0.0105	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—RGS1—bone cancer	0.001	0.0071	CbGpPWpGaD
Cinacalcet—CASR—GPCR downstream signaling—GRM4—bone cancer	0.001	0.0071	CbGpPWpGaD
Cinacalcet—Hypercalcaemia—Doxorubicin—bone cancer	0.000996	0.0104	CcSEcCtD
Cinacalcet—Dehydration—Cisplatin—bone cancer	0.000983	0.0103	CcSEcCtD
Cinacalcet—Thrombosis—Doxorubicin—bone cancer	0.000978	0.0102	CcSEcCtD
Cinacalcet—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000974	0.00688	CbGpPWpGaD
Cinacalcet—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000962	0.0068	CbGpPWpGaD
Cinacalcet—Cramp muscle—Cisplatin—bone cancer	0.000952	0.00993	CcSEcCtD
Cinacalcet—Ventricular arrhythmia—Doxorubicin—bone cancer	0.000935	0.00975	CcSEcCtD
Cinacalcet—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000925	0.00654	CbGpPWpGaD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000913	0.00645	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—GRM4—bone cancer	0.000912	0.00645	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—RGS1—bone cancer	0.000912	0.00645	CbGpPWpGaD
Cinacalcet—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000887	0.00626	CbGpPWpGaD
Cinacalcet—Bone disorder—Methotrexate—bone cancer	0.000885	0.00923	CcSEcCtD
Cinacalcet—Neoplasm malignant—Epirubicin—bone cancer	0.000876	0.00913	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—GRM1—bone cancer	0.000871	0.00615	CbGpPWpGaD
Cinacalcet—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000858	0.00606	CbGpPWpGaD
Cinacalcet—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000849	0.006	CbGpPWpGaD
Cinacalcet—Bone disorder—Epirubicin—bone cancer	0.000828	0.00863	CcSEcCtD
Cinacalcet—Hypocalcaemia—Epirubicin—bone cancer	0.000817	0.00852	CcSEcCtD
Cinacalcet—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000815	0.00576	CbGpPWpGaD
Cinacalcet—Neoplasm malignant—Doxorubicin—bone cancer	0.00081	0.00845	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—GRM1—bone cancer	0.000791	0.00559	CbGpPWpGaD
Cinacalcet—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000784	0.00554	CbGpPWpGaD
Cinacalcet—Bone disorder—Doxorubicin—bone cancer	0.000766	0.00799	CcSEcCtD
Cinacalcet—Hypocalcaemia—Doxorubicin—bone cancer	0.000756	0.00788	CcSEcCtD
Cinacalcet—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000727	0.00513	CbGpPWpGaD
Cinacalcet—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000704	0.00498	CbGpPWpGaD
Cinacalcet—Immune system disorder—Cisplatin—bone cancer	0.000661	0.00689	CcSEcCtD
Cinacalcet—Arrhythmia—Cisplatin—bone cancer	0.000653	0.00681	CcSEcCtD
Cinacalcet—Malnutrition—Cisplatin—bone cancer	0.000637	0.00664	CcSEcCtD
Cinacalcet—Muscle spasms—Cisplatin—bone cancer	0.000612	0.00638	CcSEcCtD
Cinacalcet—Fluoxetine—CYP3A4—bone cancer	0.000609	0.111	CrCbGaD
Cinacalcet—Anaemia—Cisplatin—bone cancer	0.000588	0.00614	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—GNA11—bone cancer	0.000561	0.00397	CbGpPWpGaD
Cinacalcet—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000561	0.00396	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—SMO—bone cancer	0.000557	0.00394	CbGpPWpGaD
Cinacalcet—Cardiac failure—Epirubicin—bone cancer	0.000556	0.0058	CcSEcCtD
Cinacalcet—Convulsion—Cisplatin—bone cancer	0.000552	0.00575	CcSEcCtD
Cinacalcet—Pain in extremity—Epirubicin—bone cancer	0.000543	0.00566	CcSEcCtD
Cinacalcet—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000543	0.00566	CcSEcCtD
Cinacalcet—Myalgia—Cisplatin—bone cancer	0.000542	0.00565	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—RGS1—bone cancer	0.000539	0.00381	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—GRM4—bone cancer	0.000539	0.00381	CbGpPWpGaD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000538	0.00561	CcSEcCtD
Cinacalcet—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000533	0.00377	CbGpPWpGaD
Cinacalcet—Infection—Cisplatin—bone cancer	0.000516	0.00538	CcSEcCtD
Cinacalcet—Cardiac failure—Doxorubicin—bone cancer	0.000515	0.00537	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—GNA11—bone cancer	0.00051	0.0036	CbGpPWpGaD
Cinacalcet—Nervous system disorder—Cisplatin—bone cancer	0.00051	0.00531	CcSEcCtD
Cinacalcet—CASR—GPCR downstream signaling—IL3—bone cancer	0.000509	0.0036	CbGpPWpGaD
Cinacalcet—Dehydration—Epirubicin—bone cancer	0.000505	0.00526	CcSEcCtD
Cinacalcet—Skin disorder—Cisplatin—bone cancer	0.000505	0.00526	CcSEcCtD
Cinacalcet—Pain in extremity—Doxorubicin—bone cancer	0.000502	0.00524	CcSEcCtD
Cinacalcet—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000502	0.00524	CcSEcCtD
Cinacalcet—CASR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000502	0.00354	CbGpPWpGaD
Cinacalcet—Anorexia—Cisplatin—bone cancer	0.000495	0.00516	CcSEcCtD
Cinacalcet—Hypotension—Cisplatin—bone cancer	0.000485	0.00506	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000473	0.00494	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—GRM1—bone cancer	0.000467	0.0033	CbGpPWpGaD
Cinacalcet—Dehydration—Doxorubicin—bone cancer	0.000467	0.00487	CcSEcCtD
Cinacalcet—Paraesthesia—Cisplatin—bone cancer	0.000467	0.00486	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Methotrexate—bone cancer	0.000466	0.00486	CcSEcCtD
Cinacalcet—Dyspnoea—Cisplatin—bone cancer	0.000463	0.00483	CcSEcCtD
Cinacalcet—CASR—Signaling by GPCR—IL3—bone cancer	0.000462	0.00326	CbGpPWpGaD
Cinacalcet—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00046	0.00325	CbGpPWpGaD
Cinacalcet—Decreased appetite—Cisplatin—bone cancer	0.000452	0.00471	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Cisplatin—bone cancer	0.000449	0.00468	CcSEcCtD
Cinacalcet—Depression—Methotrexate—bone cancer	0.000446	0.00465	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Epirubicin—bone cancer	0.000436	0.00455	CcSEcCtD
Cinacalcet—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000419	0.00296	CbGpPWpGaD
Cinacalcet—Body temperature increased—Cisplatin—bone cancer	0.000411	0.00428	CcSEcCtD
Cinacalcet—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000403	0.00421	CcSEcCtD
Cinacalcet—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0004	0.00282	CbGpPWpGaD
Cinacalcet—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000394	0.00279	CbGpPWpGaD
Cinacalcet—Hypersensitivity—Cisplatin—bone cancer	0.000383	0.00399	CcSEcCtD
Cinacalcet—Asthenia—Cisplatin—bone cancer	0.000373	0.00389	CcSEcCtD
Cinacalcet—Propranolol—CYP3A4—bone cancer	0.000372	0.068	CrCbGaD
Cinacalcet—Oedema peripheral—Epirubicin—bone cancer	0.00037	0.00386	CcSEcCtD
Cinacalcet—Immune system disorder—Methotrexate—bone cancer	0.000362	0.00378	CcSEcCtD
Cinacalcet—Diarrhoea—Cisplatin—bone cancer	0.000355	0.00371	CcSEcCtD
Cinacalcet—Malnutrition—Methotrexate—bone cancer	0.000349	0.00364	CcSEcCtD
Cinacalcet—Oedema peripheral—Doxorubicin—bone cancer	0.000342	0.00357	CcSEcCtD
Cinacalcet—Immune system disorder—Epirubicin—bone cancer	0.000339	0.00354	CcSEcCtD
Cinacalcet—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000338	0.00239	CbGpPWpGaD
Cinacalcet—Arrhythmia—Epirubicin—bone cancer	0.000335	0.0035	CcSEcCtD
Cinacalcet—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000334	0.00236	CbGpPWpGaD
Cinacalcet—Vomiting—Cisplatin—bone cancer	0.00033	0.00344	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—SMO—bone cancer	0.000329	0.00233	CbGpPWpGaD
Cinacalcet—Rash—Cisplatin—bone cancer	0.000328	0.00342	CcSEcCtD
Cinacalcet—Dermatitis—Cisplatin—bone cancer	0.000327	0.00341	CcSEcCtD
Cinacalcet—Malnutrition—Epirubicin—bone cancer	0.000327	0.00341	CcSEcCtD
Cinacalcet—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000324	0.00229	CbGpPWpGaD
Cinacalcet—Anaemia—Methotrexate—bone cancer	0.000323	0.00337	CcSEcCtD
Cinacalcet—Muscle spasms—Epirubicin—bone cancer	0.000314	0.00328	CcSEcCtD
Cinacalcet—Immune system disorder—Doxorubicin—bone cancer	0.000314	0.00327	CcSEcCtD
Cinacalcet—Arrhythmia—Doxorubicin—bone cancer	0.00031	0.00324	CcSEcCtD
Cinacalcet—Nausea—Cisplatin—bone cancer	0.000309	0.00322	CcSEcCtD
Cinacalcet—Cough—Methotrexate—bone cancer	0.000305	0.00318	CcSEcCtD
Cinacalcet—Convulsion—Methotrexate—bone cancer	0.000303	0.00316	CcSEcCtD
Cinacalcet—Malnutrition—Doxorubicin—bone cancer	0.000302	0.00315	CcSEcCtD
Cinacalcet—Anaemia—Epirubicin—bone cancer	0.000302	0.00315	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—GNA11—bone cancer	0.000301	0.00213	CbGpPWpGaD
Cinacalcet—Arthralgia—Methotrexate—bone cancer	0.000297	0.0031	CcSEcCtD
Cinacalcet—Myalgia—Methotrexate—bone cancer	0.000297	0.0031	CcSEcCtD
Cinacalcet—Chest pain—Methotrexate—bone cancer	0.000297	0.0031	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000295	0.00308	CcSEcCtD
Cinacalcet—Muscle spasms—Doxorubicin—bone cancer	0.000291	0.00303	CcSEcCtD
Cinacalcet—Cough—Epirubicin—bone cancer	0.000285	0.00297	CcSEcCtD
Cinacalcet—Convulsion—Epirubicin—bone cancer	0.000283	0.00295	CcSEcCtD
Cinacalcet—Infection—Methotrexate—bone cancer	0.000283	0.00295	CcSEcCtD
Cinacalcet—Hypertension—Epirubicin—bone cancer	0.000282	0.00294	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—ATF1—bone cancer	0.00028	0.00198	CbGpPWpGaD
Cinacalcet—Nervous system disorder—Methotrexate—bone cancer	0.00028	0.00292	CcSEcCtD
Cinacalcet—Anaemia—Doxorubicin—bone cancer	0.00028	0.00292	CcSEcCtD
Cinacalcet—Arthralgia—Epirubicin—bone cancer	0.000278	0.0029	CcSEcCtD
Cinacalcet—Chest pain—Epirubicin—bone cancer	0.000278	0.0029	CcSEcCtD
Cinacalcet—Myalgia—Epirubicin—bone cancer	0.000278	0.0029	CcSEcCtD
Cinacalcet—Skin disorder—Methotrexate—bone cancer	0.000277	0.00289	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000276	0.00288	CcSEcCtD
Cinacalcet—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000274	0.00194	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—IL3—bone cancer	0.000273	0.00193	CbGpPWpGaD
Cinacalcet—Anorexia—Methotrexate—bone cancer	0.000272	0.00283	CcSEcCtD
Cinacalcet—Hypotension—Methotrexate—bone cancer	0.000266	0.00278	CcSEcCtD
Cinacalcet—Infection—Epirubicin—bone cancer	0.000265	0.00276	CcSEcCtD
Cinacalcet—Cough—Doxorubicin—bone cancer	0.000264	0.00275	CcSEcCtD
Cinacalcet—Convulsion—Doxorubicin—bone cancer	0.000262	0.00273	CcSEcCtD
Cinacalcet—Nervous system disorder—Epirubicin—bone cancer	0.000262	0.00273	CcSEcCtD
Cinacalcet—Hypertension—Doxorubicin—bone cancer	0.000261	0.00272	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00026	0.00271	CcSEcCtD
Cinacalcet—Skin disorder—Epirubicin—bone cancer	0.000259	0.0027	CcSEcCtD
Cinacalcet—Arthralgia—Doxorubicin—bone cancer	0.000258	0.00269	CcSEcCtD
Cinacalcet—Chest pain—Doxorubicin—bone cancer	0.000258	0.00269	CcSEcCtD
Cinacalcet—Myalgia—Doxorubicin—bone cancer	0.000258	0.00269	CcSEcCtD
Cinacalcet—Paraesthesia—Methotrexate—bone cancer	0.000256	0.00267	CcSEcCtD
Cinacalcet—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000256	0.00267	CcSEcCtD
Cinacalcet—Anorexia—Epirubicin—bone cancer	0.000254	0.00265	CcSEcCtD
Cinacalcet—Dyspnoea—Methotrexate—bone cancer	0.000254	0.00265	CcSEcCtD
Cinacalcet—Dyspepsia—Methotrexate—bone cancer	0.000251	0.00262	CcSEcCtD
Cinacalcet—Hypotension—Epirubicin—bone cancer	0.000249	0.0026	CcSEcCtD
Cinacalcet—Decreased appetite—Methotrexate—bone cancer	0.000248	0.00258	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Methotrexate—bone cancer	0.000246	0.00257	CcSEcCtD
Cinacalcet—Fatigue—Methotrexate—bone cancer	0.000246	0.00256	CcSEcCtD
Cinacalcet—Infection—Doxorubicin—bone cancer	0.000245	0.00256	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000243	0.00253	CcSEcCtD
Cinacalcet—Nervous system disorder—Doxorubicin—bone cancer	0.000242	0.00252	CcSEcCtD
Cinacalcet—Skin disorder—Doxorubicin—bone cancer	0.00024	0.0025	CcSEcCtD
Cinacalcet—Paraesthesia—Epirubicin—bone cancer	0.00024	0.0025	CcSEcCtD
Cinacalcet—Dyspnoea—Epirubicin—bone cancer	0.000238	0.00248	CcSEcCtD
Cinacalcet—Anorexia—Doxorubicin—bone cancer	0.000235	0.00245	CcSEcCtD
Cinacalcet—Dyspepsia—Epirubicin—bone cancer	0.000235	0.00245	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—TGFBR2—bone cancer	0.000233	0.00165	CbGpPWpGaD
Cinacalcet—Gastrointestinal pain—Methotrexate—bone cancer	0.000233	0.00243	CcSEcCtD
Cinacalcet—Decreased appetite—Epirubicin—bone cancer	0.000232	0.00242	CcSEcCtD
Cinacalcet—Hypotension—Doxorubicin—bone cancer	0.000231	0.00241	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Epirubicin—bone cancer	0.00023	0.0024	CcSEcCtD
Cinacalcet—Fatigue—Epirubicin—bone cancer	0.00023	0.0024	CcSEcCtD
Cinacalcet—Constipation—Epirubicin—bone cancer	0.000228	0.00238	CcSEcCtD
Cinacalcet—Urticaria—Methotrexate—bone cancer	0.000226	0.00236	CcSEcCtD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000226	0.00159	CbGpPWpGaD
Cinacalcet—Abdominal pain—Methotrexate—bone cancer	0.000225	0.00235	CcSEcCtD
Cinacalcet—Body temperature increased—Methotrexate—bone cancer	0.000225	0.00235	CcSEcCtD
Cinacalcet—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000225	0.00235	CcSEcCtD
Cinacalcet—Paraesthesia—Doxorubicin—bone cancer	0.000222	0.00231	CcSEcCtD
Cinacalcet—Dyspnoea—Doxorubicin—bone cancer	0.00022	0.0023	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—IGF1R—bone cancer	0.00022	0.00155	CbGpPWpGaD
Cinacalcet—Gastrointestinal pain—Epirubicin—bone cancer	0.000218	0.00228	CcSEcCtD
Cinacalcet—Dyspepsia—Doxorubicin—bone cancer	0.000217	0.00227	CcSEcCtD
Cinacalcet—Decreased appetite—Doxorubicin—bone cancer	0.000215	0.00224	CcSEcCtD
Cinacalcet—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000213	0.00222	CcSEcCtD
Cinacalcet—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000213	0.00151	CbGpPWpGaD
Cinacalcet—Fatigue—Doxorubicin—bone cancer	0.000213	0.00222	CcSEcCtD
Cinacalcet—Urticaria—Epirubicin—bone cancer	0.000212	0.00221	CcSEcCtD
Cinacalcet—Constipation—Doxorubicin—bone cancer	0.000211	0.0022	CcSEcCtD
Cinacalcet—Body temperature increased—Epirubicin—bone cancer	0.000211	0.0022	CcSEcCtD
Cinacalcet—Abdominal pain—Epirubicin—bone cancer	0.000211	0.0022	CcSEcCtD
Cinacalcet—Hypersensitivity—Methotrexate—bone cancer	0.00021	0.00219	CcSEcCtD
Cinacalcet—Asthenia—Methotrexate—bone cancer	0.000205	0.00213	CcSEcCtD
Cinacalcet—Gastrointestinal pain—Doxorubicin—bone cancer	0.000202	0.00211	CcSEcCtD
Cinacalcet—Pruritus—Methotrexate—bone cancer	0.000202	0.0021	CcSEcCtD
Cinacalcet—Hypersensitivity—Epirubicin—bone cancer	0.000197	0.00205	CcSEcCtD
Cinacalcet—Urticaria—Doxorubicin—bone cancer	0.000196	0.00205	CcSEcCtD
Cinacalcet—Abdominal pain—Doxorubicin—bone cancer	0.000195	0.00204	CcSEcCtD
Cinacalcet—Body temperature increased—Doxorubicin—bone cancer	0.000195	0.00204	CcSEcCtD
Cinacalcet—Diarrhoea—Methotrexate—bone cancer	0.000195	0.00203	CcSEcCtD
Cinacalcet—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000192	0.00136	CbGpPWpGaD
Cinacalcet—Asthenia—Epirubicin—bone cancer	0.000191	0.002	CcSEcCtD
Cinacalcet—Pruritus—Epirubicin—bone cancer	0.000189	0.00197	CcSEcCtD
Cinacalcet—Dizziness—Methotrexate—bone cancer	0.000189	0.00197	CcSEcCtD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000185	0.00131	CbGpPWpGaD
Cinacalcet—Diarrhoea—Epirubicin—bone cancer	0.000183	0.0019	CcSEcCtD
Cinacalcet—Hypersensitivity—Doxorubicin—bone cancer	0.000182	0.0019	CcSEcCtD
Cinacalcet—Vomiting—Methotrexate—bone cancer	0.000181	0.00189	CcSEcCtD
Cinacalcet—Rash—Methotrexate—bone cancer	0.00018	0.00187	CcSEcCtD
Cinacalcet—Dermatitis—Methotrexate—bone cancer	0.00018	0.00187	CcSEcCtD
Cinacalcet—Headache—Methotrexate—bone cancer	0.000179	0.00186	CcSEcCtD
Cinacalcet—Asthenia—Doxorubicin—bone cancer	0.000177	0.00185	CcSEcCtD
Cinacalcet—Dizziness—Epirubicin—bone cancer	0.000176	0.00184	CcSEcCtD
Cinacalcet—Pruritus—Doxorubicin—bone cancer	0.000175	0.00182	CcSEcCtD
Cinacalcet—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000174	0.00123	CbGpPWpGaD
Cinacalcet—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000172	0.00122	CbGpPWpGaD
Cinacalcet—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.00017	0.0012	CbGpPWpGaD
Cinacalcet—Vomiting—Epirubicin—bone cancer	0.00017	0.00177	CcSEcCtD
Cinacalcet—Nausea—Methotrexate—bone cancer	0.000169	0.00177	CcSEcCtD
Cinacalcet—Diarrhoea—Doxorubicin—bone cancer	0.000169	0.00176	CcSEcCtD
Cinacalcet—Rash—Epirubicin—bone cancer	0.000168	0.00175	CcSEcCtD
Cinacalcet—Dermatitis—Epirubicin—bone cancer	0.000168	0.00175	CcSEcCtD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000167	0.00118	CbGpPWpGaD
Cinacalcet—Headache—Epirubicin—bone cancer	0.000167	0.00174	CcSEcCtD
Cinacalcet—Dizziness—Doxorubicin—bone cancer	0.000163	0.0017	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—KIT—bone cancer	0.000159	0.00113	CbGpPWpGaD
Cinacalcet—Nausea—Epirubicin—bone cancer	0.000158	0.00165	CcSEcCtD
Cinacalcet—Vomiting—Doxorubicin—bone cancer	0.000157	0.00164	CcSEcCtD
Cinacalcet—Rash—Doxorubicin—bone cancer	0.000156	0.00162	CcSEcCtD
Cinacalcet—Dermatitis—Doxorubicin—bone cancer	0.000156	0.00162	CcSEcCtD
Cinacalcet—Headache—Doxorubicin—bone cancer	0.000155	0.00161	CcSEcCtD
Cinacalcet—CASR—Signaling Pathways—BRAF—bone cancer	0.00015	0.00106	CbGpPWpGaD
Cinacalcet—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000148	0.00105	CbGpPWpGaD
Cinacalcet—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000147	0.00104	CbGpPWpGaD
Cinacalcet—Nausea—Doxorubicin—bone cancer	0.000147	0.00153	CcSEcCtD
Cinacalcet—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000146	0.00103	CbGpPWpGaD
Cinacalcet—CASR—Signaling by GPCR—EGFR—bone cancer	0.000145	0.00103	CbGpPWpGaD
Cinacalcet—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000145	0.00103	CbGpPWpGaD
Cinacalcet—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000144	0.00102	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000131	0.000929	CbGpPWpGaD
Cinacalcet—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000131	0.000929	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MDM2—bone cancer	0.000125	0.000886	CbGpPWpGaD
Cinacalcet—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000125	0.000881	CbGpPWpGaD
Cinacalcet—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000123	0.000868	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—JUN—bone cancer	0.000109	0.00077	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—MMP9—bone cancer	0.000106	0.00075	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000103	0.000728	CbGpPWpGaD
Cinacalcet—CYP3A4—Biological oxidations—GSTP1—bone cancer	9.62e-05	0.00068	CbGpPWpGaD
Cinacalcet—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	9.49e-05	0.00067	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—NDUFA12—bone cancer	8.74e-05	0.000617	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—EGFR—bone cancer	8.57e-05	0.000606	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—NT5C3A—bone cancer	8.55e-05	0.000604	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—NT5C3A—bone cancer	7.24e-05	0.000511	CbGpPWpGaD
Cinacalcet—CASR—Signaling Pathways—TP53—bone cancer	7.2e-05	0.000509	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—NDUFA12—bone cancer	6.74e-05	0.000476	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—NT5C3A—bone cancer	5.59e-05	0.000395	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—ENO2—bone cancer	3.74e-05	0.000264	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—DHFR—bone cancer	3.47e-05	0.000245	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—GNA11—bone cancer	3.25e-05	0.000229	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—ENO2—bone cancer	3.17e-05	0.000224	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—CYP3A4—bone cancer	2.94e-05	0.000208	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—DHFR—bone cancer	2.94e-05	0.000208	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—GNA11—bone cancer	2.75e-05	0.000194	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—GSTP1—bone cancer	2.52e-05	0.000178	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000176	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.48e-05	0.000175	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—ENO2—bone cancer	2.45e-05	0.000173	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—DHFR—bone cancer	2.27e-05	0.00016	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—GSTP1—bone cancer	2.13e-05	0.000151	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—GNA11—bone cancer	2.12e-05	0.00015	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—GSTP1—bone cancer	1.65e-05	0.000116	CbGpPWpGaD
Cinacalcet—CYP2D6—Metabolism—PTGS2—bone cancer	1.3e-05	9.21e-05	CbGpPWpGaD
Cinacalcet—CYP1A2—Metabolism—PTGS2—bone cancer	1.1e-05	7.8e-05	CbGpPWpGaD
Cinacalcet—CYP3A4—Metabolism—PTGS2—bone cancer	8.52e-06	6.02e-05	CbGpPWpGaD
